Clinical Trials
Study Title:
A Phase 1/2 Study of REGN5093 M114 (METxMET Antibody Drug Conjugate) in Patients with MET Overexpressing Advanced Cancer
For more information about the trial above please contact the study team:
Medical University of South Carolina Principal Investigator, Mariam Alexander, at alexanma@musc.edu. Study Coordinator, Jessica Shealor, at shealorj@musc.edu.
Trial opened at the following institutions: Medical University of South Carolina |